COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,629 Articles (22,913 medRxiv, 8,716 bioRxiv)

Most recent first Previous |  Page 2392: Articles 23911-23920  | Next

Ex vivo detection of SARS-CoV-2-specific CD8+ T cells: rapid induction, prolonged contraction, and formation of functional memory
Schulien, I., Kemming, J., Oberhardt, V., Wild, K., Seidel, L. M., Killmer, S., Sagar, , Daul, F., Salvat Lago, M., Decker, A., Luxenburger, H., Binder, B., Bettinger, D., Sogukpinar, O., Rieg, S., Panning, M., Huzly, D., Schwemmle, M., Kochs, G., Waller, C. F., Nieters, A., Duerschmied, D., Emmerich, F., Mei, H., Schulz, A., Llewellyn-Lacey, S., Price, D. A., Boettler, T., Bengsch, B., Thimme, R., Hofmann, M., Neumann-Haefelin, C.
10.1101/2020.08.13.249433 — Posted: 2020-08-14
Tissue-resident memory CD8 T-cell responses elicited by a single injection of a multi-target COVID-19 vaccine
Gauttier, V., Morello, A., Girault, I., Mary, C., Belarif, L., Desselle, A., Wilhelm, E., Bourquard, T., Pengam, S., Teppaz, G., Thepenier, V., Biteau, K., De Barbeyrac, E., Kiepferle, D., Vasseur, B., Le Flem, F.-X., Debieuvre, D., Costantini, D., Poirier, N.
10.1101/2020.08.14.240093 — Posted: 2020-08-14
Designed Variants of Recombinant ACE2-Fc that Decouple Anti-SARS-CoV-2 Activities from Unwanted Cardiovascular Effects
Liu, P., Xie, X., Gao, L., Jin, J.
10.1101/2020.08.13.248351 — Posted: 2020-08-14
Methylene Blue has a potent antiviral activity against SARS-CoV-2 in the absence of UV-activation in vitro
Cagno, V., Medaglia, C., Cerny, A., Cerny, T., Tapparel, C., Cerny, E.
10.1101/2020.08.14.251090 — Posted: 2020-08-14
SRSF protein kinases 1 and 2 are essential host factors for human coronaviruses including SARS-CoV-2
Heaton, B. E., Trimarco, J. D., Hamele, C. E., Harding, A. T., Tata, A., Zhu, X., Tata, P. R., Smith, C. M., Heaton, N. S.
10.1101/2020.08.14.251207 — Posted: 2020-08-14 Discussion: Offsite
Discovery of Clioquinol and Analogues as Novel Inhibitors of Severe Acute Respiratory Syndrome Coronavirus 2 Infection, ACE2 and ACE2 - Spike Protein Interaction In Vitro
Olaleye, O. A., Kaur, M., Onyenaka, C. C., Adebusuyi, T. O.
10.1101/2020.08.14.250480 — Posted: 2020-08-14
Rational Design of SARS-CoV-2 Spike Glycoproteins To Increase Immunogenicity By T Cell Epitope Engineering
Ong, E., Huang, X., Pearce, R., Zhang, Y., He, Y.
10.1101/2020.08.14.251496 — Posted: 2020-08-14
In Silico Design of siRNAs Targeting Existing and Future Respiratory Viruses with VirusSi
Zhang, D., Lu, J.
10.1101/2020.08.13.250076 — Posted: 2020-08-14
Differential methylation as a mediator of COVID-19 susceptibility
Steyaert, S., Trooskens, G., Delanghe, J. R., Van Criekinge, W.
10.1101/2020.08.14.251538 — Posted: 2020-08-14
Pandemic danger to the deep: the risk of marine mammals contracting SARS-CoV-2 from wastewater
Mathavarajah, S., Stoddart, A. K., Gagnon, G. A., Dellaire, G.
10.1101/2020.08.13.249904 — Posted: 2020-08-14 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).